CRISPR Therapeutics advances top dose of gene editing treatment for high cholesterol
CRISPR Therapeutics presented one-year data from an early-stage trial of its gene editing treatment for high cholesterol, showing inconsistent durability. Despite the mixed results, the company plans to advance the highest dose tested. The findings were shared at the European Society of Cardiology meeting in Munich.
Related stories
Cytokinetics presents positive Myqorzo results, seeks broader heart disease indication · Drug development
Biotech releases Phase 1 respiratory therapy results following premature poster exposure · Drug development
ESC Meeting to Present Key Statin Trial and Heart Attack Care Studies · Drug development
Bausch + Lomb pushes dry eye therapy to Phase 3 after Phase 2 miss · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “#ESC26: CRISPR Therapeutics to pursue highest dose of its lipid lowering gene editing therapy.” Browse more stories.